Table 1.

Characteristics of the included trials in the meta-analysis.

Clinical trials	Authors	Phase	Age (median)	Stage	Treatment groups	EGFR-mutant Patients	Disease-free survival	Overall survival	Quality assessment
							HR (95%CI)	HR (95%CI)
RADIANT (11)	Kelly et al. (2015)	3	61	IB–IIIA	Erlotinib vs Placebo	161	0.61 (0.38–0.98)	1.09 (0.55–2.16)	6
CTSUBR19 (10)	Goss et al. (2013)	3	NA	IB–IIIA	Gefitinib vs Placebo	15	1.84 (0.44–7.73)	0.83 (0.54–1.26)	5
Li et al. (24)	Li et al. (2014)	2	59.5	IIIA	Chemotherapy + gefitinib vs chemotherapy	60	0.37 (0.16–0.85)	0.61 (0.42–0.87)	3
Feng et al. (25)	Feng et al. (2015)	2	57	IB–IIIA	Chemotherapy + icotinib vs chemotherapy	41	0·22 (0·04–1.15)	0·86 (0·62–1·20)	3
CTONG 1104 (13)	Zhong et al. (2018)	3	58	II–IIIA	Gefitinib vs VP	222	0.60 (0.42–0.87)	0.92 (0.62–1.36)	5
EVAN (12)	Yue et al. (2018)	2	59	IIIA	Erlotinib vs VP	102	0.27(0.14–0.53)	0.17(0.05–0.58)	5
ADAURA (26)	Wu et al. (2020)	3	NA	IB–IIIA	Osimertinib vs Placebo	682	0.20(0.15–0.27)	NA	6

VP, Vinorelbine plus cisplatin; NA, not available.